North America And Europe Celiac Disease Market
Tamaño del mercado en miles de millones de dólares
Tasa de crecimiento anual compuesta (CAGR) :
% 
 Período de pronóstico |
2024 –2031 |
 Tamaño del mercado (año base) |
USD 94,325.34 Thousand |
 Tamaño del mercado (año de pronóstico) |
USD 193,364.33 Thousand |
 Tasa de crecimiento anual compuesta (CAGR) |
% |
| Jugadoras de los principales mercados |
North America and Europe Celiac Disease Market, By Treatment Type (Corticosteriods, Immunosuppressants and Others), Disease Type (Classical Celiac Disease, Non-Classical Celiac Disease, Refractory Celiac Disease, Potential Celiac Disease and Dermatitis Herpetiformis), Drug Type (Generics and Branded), Prescription Type (Prescription and Over The Counter), Dosage Form (Tablet, Capsules, Injection and Other), Route of Administration (Oral, Intravenous and Topical), Population Type (Children, Adults and Geriatric), End User (Hospitals, Clinics, Diagnostic Centres, Home Care Settings and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others) – Industry trends and forecast to 2031.
North America and Europe Celiac Disease Market Analysis and Insights
The market dynamics in North America and Europe for celiac disease are influenced by factors such as the rising prevalence of the condition, advancements in diagnostic technologies, and an expanding market for gluten-free products. Healthcare providers in these regions play a crucial role in creating awareness, conducting screenings, and implementing treatment strategies. Additionally, the growing interest in gluten-free diets as a lifestyle choice among the general population contributes to the expansion of the market.
Overall, the North America and Europe celiac disease market reflects a dynamic interplay of awareness, diagnosis, and research initiatives to improve the lives of individuals affected by this autoimmune condition. However, the market faces challenges such as the complexity of the disease and side effects associated with the drugs used for the treatment of celiac disease.
The North America celiac disease market is expected to gain market growth in the forecast period of 2024 to 2031. Data Bridge Market Research analyses that the market is growing with a CAGR of 9.8% in the forecast period of 2024 to 2031 and is expected to reach USD 193,364.33 Thousand by 2031 from USD 94,325.34 Thousand in 2023.
The Europe celiac disease market is expected to gain market growth in the forecast period of 2024 to 2031. Data Bridge Market Research analyses that the market is growing with a CAGR of 8.8% in the forecast period of 2024 to 2031 and is expected to reach USD 150,949.09 thousand by 2031 from USD 78,786.35 thousand in 2023.
|
Report Metric |
Details |
|
Forecast Period |
2024 to 2031 |
|
Base Year |
2023 |
|
Historic Years |
2022 (Customizable to 2020-2021) |
|
Quantitative Units |
Revenue in USD Thousand, Volumes in Units |
|
Segments Covered |
Treatment Type (Corticosteriods, Immunosuppressants and Others), Disease Type (Classical Celiac Disease, Non-Classical Celiac Disease, Refractory Celiac Disease, Potential Celiac Disease and Dermatitis Herpetiformis), Drug Type (Generics and Branded), Prescription Type (Prescription and Over The Counter), Dosage Form (Tablet, Capsules, Injection and Other), Route of Administration (Oral, Intravenous and Topical), Population Type (Children, Adults and Geriatric), End User (Hospitals, Clinics, Diagnostic Centres, Home Care Settings and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others) |
|
Countries Covered |
U.S., Canada, Mexico, Germany, France, Italy, Spain, U.K., Switzerland, Netherlands, Russia, Turkey, Poland, Sweden, Belgium, Denmark, Finland, Norway and Rest of Europe |
|
Market Players Covered |
Takeda Pharmaceutical Company Limited, Salix Pharmaceuticals (subsidiary of Bausch Health Companies Inc.), Tillotts Pharma AG, GSK plc., ImmunogenX, Inc., Janssen Pharmaceuticals, Inc. (subsidiary of Johnson & Johnson Services, Inc.), Teva Pharmaceuticals USA, Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Amgen Inc., AstraZeneca, Novartis AG, AdvaCare Pharma, ANOKION, Topas Therapeutics, Immunic Therapeutics and Equillium Bio. among others |
Market Definition
Celiac disease, is a chronic autoimmune disorder characterized by an abnormal immune response to the ingestion of gluten—a protein found in wheat, barley, and rye. When individuals with celiac disease consume gluten, their immune system mistakenly attacks the lining of the small intestine, leading to inflammation and damage to the villi, finger-like projections responsible for nutrient absorption. This immune reaction results in a range of gastrointestinal and systemic symptoms, including abdominal pain, diarrhea, weight loss, fatigue, and nutritional deficiencies.
The diagnosis of celiac disease often involves a combination of blood tests to detect specific antibodies and confirmatory intestinal biopsy. The primary and lifelong treatment for celiac disease is a strict gluten-free diet. By eliminating gluten from their diet, individuals with celiac disease can manage symptoms, promote intestinal healing, and prevent complications. Adherence to a gluten-free lifestyle is crucial, as even small amounts of gluten can trigger immune responses and exacerbate the condition. Celiac disease can affect people of all ages, and while it is a lifelong condition, with proper management, individuals can lead healthy and fulfilling lives.
North America and Europe Celiac Disease Market Dynamics
Drivers
- Increasing Prevalence Of Celiac Disease
Celiac disease is an autoimmune disorder characterized by an intolerance to gluten, a protein found in wheat, barley, and rye. The prevalence of celiac disease has been on the rise in recent years, and several factors contribute to this increase.
In North America and Europe, where the westernized diet is prevalent, the shift towards increased gluten consumption further amplifies the market's growth. Thus increasing prevalence of celiac disease is expected to act as driver for the North America and Europe celiac disease market.
- Rising Demand For Gluten Containing Products
Gluten-containing products are made from ingredients that naturally contain gluten. This includes wheat-based products such as bread, pasta, pastries, and cereals. Barley and rye-based products also contain gluten.
In baking, gluten contributes to the rise and texture of bread and other baked goods. These ingredients are used in a variety of food items, from baked goods to pasta to certain sauces and processed foods.
The demand for gluten-containing products remains strong in North America and Europe due to consumer preferences, culinary traditions, and the cultural significance of certain foods. It reflects the broader consumer preference for traditional, gluten-rich foods in the region which will further increases the risk of celiac disease. Thus rising demand for gluten-containing products is expected to act as driver for the North America and Europe celiac disease market.
Restraint
- Complexity Of Celiac Disease
Celiac disease is a complex autoimmune disorder characterized by an abnormal immune response to gluten, a protein found in wheat, barley, rye, and their derivatives. The complexity of celiac disease arises from the intricate interplay of genetic, immunological, environmental, and dietary factors.
These complications make celiac disease a multifaceted and challenging autoimmune disorder to understand, diagnose, and manage. Thus complexity of celiac disease is expected to act as restraint for the North America and Europe celiac disease market.
Opportunity
- Emerging Biological Therapies For Celiac Disease
Emerging biological therapies for celiac disease represent a promising avenue for developing alternative treatments beyond the current standard of care, which is a lifelong strict gluten-free diet. While these therapies are still in the experimental stages and undergoing clinical trials, they hold the potential to address the complexity associated with celiac disease, offering new possibilities for individuals affected by this autoimmune disorder.
The development of biological therapies for celiac disease reflects a growing understanding of the underlying immunological mechanisms and a commitment to finding innovative solutions to improve the quality of life for individuals with this autoimmune disorder. As research progresses, these therapies may offer new options for the management of celiac disease beyond the limitations of a strict gluten-free diet. Thus emerging biological therapies for celiac disease is expected to act as opportunity for the North America and Europe celiac disease market.
Challenge
- Patient Adherence To Gluten-Free Diet
While patient adherence to a gluten-free diet is crucial for managing celiac disease, it presents challenges for the celiac disease market. The celiac disease market faces challenges because a strict gluten-free diet is currently the only effective treatment. With limited pharmaceutical interventions or alternative therapies available, the market heavily relies on patients adhering to dietary restrictions. This lack of treatment diversity limits revenue streams for pharmaceutical companies operating in the celiac disease space.
Patient adherence to a gluten-free diet poses challenges for the celiac disease market, particularly in terms of limited treatment options, economic considerations, and the impact on pharmaceutical development. Thus patient adherence to gluten-free diet is expected to act as challenge for the North America and Europe celiac disease market.
Recent Developments
- In October 2022, Takeda Pharmaceutical Company Limited, Zedira and Dr. Falk Pharma GmbH announced a collaboration and license agreement to develop ZED1227/TAK-227, a Phase 2b investigational drug in celiac disease. This collaboration will help the company to come up with the treatment of celiac disease
- In June 2020, Janssen Pharmaceuticals, Inc. announced collaboration with Monash University and signed a multi-year research to advance the understanding of the immune mechanisms underpinning Coeliac Disease and inform the development of new methods of diagnosis and treatment. The collaboration brings together leading researchers and industry partners to tackle this major health issue to develop innovative immunotherapeutics to prevent and treat celiac isease
North America and Europe Celiac Disease Market Scope
North America and Europe celiac disease market is categorized into nine notable segments based on treatment type, diagnosis, disease type, drug type, prescription type, dosage form, route of administration, population type, end user and distribution channel.The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Treatment Type
- Corticosteriods
- Immunosuppressants
- Others
On the basis of treatment type, the market is segmented into corticosteroids, immunosuppressants, and others.
Disease Type
- Refractory Celiac Disease
- Dermatitis Herpetiformis
- Potential Celiac Disease
- Classical Celiac Disease
- Non-Classical Celiac Disease
On the basis of disease type, the market is segmented into refractory celiac disease, dermatitis herpetiformis, potential celiac disease, classical celiac disease, and non-classical celiac disease.
Drug Type
- Generics
- Branded
On the basis of drug type, the market is segmented into branded and generics.
Prescription Type
- Prescription
- Over The Counter
On the basis of prescription type, the market is segmented into prescription and over the counter.
Dosage Form
- Tablet
- Capsules
- Injections
- Other
On the basis of dosage form, the market is segmented into tablet, capsules, injections, and others.
Route of Administration
- Oral
- Intravenous
- Topical
On the basis of route of administration, the market is segmented into oral, intravenous, and topical.
Population Type
- Adults
- Children
- Geriatric
On the basis of population type, the market is segmented into adults, children, and geriatric.
End-User
- Hospitals
- Clinics
- Home Care Settings
- Others
On the basis of end user, the market is segmented into hospitals, clinics, home care settings, and others.
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
On the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others.
North America and Europe Celiac Disease Market Regional Analysis/Insights
The market is analyzed and market size insights and trends are provided by country, treatment type, diagnosis, disease type, drug type, prescription type, dosage form, route of administration, population type, end user and distribution channel as referenced above.
The countries covered in this market report U.S., Canada, Mexico, Germany, France, Italy, Spain, U.K., Switzerland, Netherlands, Russia, Turkey, Poland, Sweden, Belgium, Denmark, Finland, Norway and Rest of Europe.
The U.S. region is expected to dominate the market due to the strong presence of market players in the region. The Germany region is expected to dominate the market due to high prevalence of celiac disease and advanced healthcare infrastructure.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and North America and Europe Celiac Disease Market Share Analysis
North America and Europe celiac disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breath, application dominance, product type lifeline curve. The above data points provided are only related to the company’s focus on the North America and Europe celiac disease market.
Some of the major players operating in the North America and Europe celiac disease market are Takeda Pharmaceutical Company Limited, Salix Pharmaceuticals (subsidiary of Bausch Health Companies Inc.), Tillotts Pharma AG, GSK plc., ImmunogenX, Inc., Janssen Pharmaceuticals, Inc. (subsidiary of Johnson & Johnson Services, Inc.), Teva Pharmaceuticals USA, Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Amgen Inc., AstraZeneca, Novartis AG, AdvaCare Pharma, ANOKION, Topas Therapeutics, Immunic Therapeutics and Equillium Bio. among others.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TREATMENT TYPE LIFELINE CURVE FOR THE NORTH AMERICA CELIAC DISEASE MARKET
2.8 TREATMENT TYPE LIFELINE CURVE THE EUROPE CELIAC DISEASE MARKET
2.9 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.1 DBMR MARKET POSITION GRID
2.11 MARKET END USER COVERAGE GRID
2.12 VENDOR SHARE ANALYSIS
2.13 SECONDARY SOURCES
2.14 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTERS 5 FORCES
4.3 EPIDEMIOLOGY
5 PIPELINE ANALYSIS
6 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, REGULATORY FRAMEWORK
6.1 REGULATIONS IN NORTH AMERICA
6.1.1 U.S.
6.1.2 CANADA
6.2 REGULATIONS IN EUROPE
6.2.1 EUROPEAN UNION (EU)
6.2.2 U.K.
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING PREVALENCE OF CELIAC DISEASE
7.1.2 RISING CONSUMPTION OF GLUTEN-CONTAINING PRODUCTS
7.1.3 INCREASING RESEARCH AND DEVELOPMENT FOR CELIAC DISEASE TREATMENTS
7.1.4 GROWING AWARENESS ABOUT CELIAC DISEASE
7.2 RESTRAINTS
7.2.1 COMPLEXITY OF CELIAC DISEASE
7.2.2 LIMITED TREATMENT OPTIONS FOR CELIAC DISEASE
7.3 OPPORTUNITIES
7.3.1 EMERGING BIOLOGICAL THERAPIES FOR CELIAC DISEASE
7.3.2 RISING ADVANCEMENTS IN DIAGNOSTIC APPROACHES OF CELIAC DISEASE
7.3.3 STRATEGIC COLLABORATION FOR COMMERCIALIZATION OF NOVEL THERAPIES FOR CELIAC DISEASE
7.4 CHALLENGES
7.4.1 PATIENT ADHERENCE TO GLUTEN-FREE DIET
7.4.2 ADVERSE EFFECTS ASSOCIATED WITH MEDICATIONS USED FOR CELIAC DISEASE TREATMENT
8 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY TREATMENT TYPE
8.1 OVERVIEW
8.2 CORTICOSTERIODS
8.2.1 PREDNISONE
8.2.2 .BUDESONIDE
8.2.3 BETAMETHASONE
8.2.4 CLOBETASONE BUTYRATE
8.2.5 OTHERS
8.3 IMMUNOSUPPRESSANTS
8.3.1 AZATHIOPRINE
8.3.2 INFLIXIMAB
8.3.3 CYCLOSPORINE
8.3.4 CLADRIBINE
8.3.5 OTHERS
8.4 OTHERS
9 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY DISEASE TYPE
9.1 OVERVIEW
9.2 REFRACTORY CELIAC DISEASE
9.2.1 TYPE I
9.2.2 TYPE II
9.3 DERMATITIS HERPETIFORMIS
9.4 POTENTIAL CELIAC DISEASE
9.5 CLASSICAL CELIAC DISEASE
9.6 NON-CLASSICAL CELIAC DISEASE
10 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY DRUG TYPE
10.1 OVERVIEW
10.2 GENERICS
10.3 BRANDED
11 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE
11.1 OVERVIEW
11.2 PRESCRIPTION
11.3 OVER THE COUNTER
12 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY DOSAGE FORM
12.1 OVERVIEW
12.2 TABLET
12.3 CAPSULES
12.4 INJECTIONS
12.5 OTHER
13 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 ORAL
13.2.1 TABLET
13.2.2 CAPSULES
13.2.3 OTHERS
13.3 INTRAVENOUS
13.4 TOPICAL
14 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY POPULATION TYPE
14.1 OVERVIEW
14.2 ADULTS
14.2.1 FEMALE
14.2.2 MALE
14.3 CHILDREN
14.4 GERIATRIC
14.4.1 FEMALE
14.4.2 MALE
15 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 CLINICS
15.4 HOME CARE SETTINGS
15.5 OTHERS
16 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 HOSPITAL PHARMACY
16.3 RETAIL PHARMACY
16.4 ONLINE PHARMACY
16.5 OTHERS
17 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY GEOGRAPHY
17.1 NORTH AMERICA
17.1.1 U.S.
17.1.2 CANADA
17.1.3 MEXICO
17.2 EUROPE
17.2.1 GERMANY
17.2.2 FRANCE
17.2.3 ITALY
17.2.4 SPAIN
17.2.5 U.K.
17.2.6 SWITZERLAND
17.2.7 NETHERLANDS
17.2.8 RUSSIA
17.2.9 TURKEY
17.2.10 POLAND
17.2.11 SWEDEN
17.2.12 BELGIUM
17.2.13 DENMARK
17.2.14 FINLAND
17.2.15 NORWAY
17.2.16 REST OF EUROPE
18 NORTH AMERICA CELIAC DISEASE MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
19 EUROPE CELIAC DISEASE MARKET: COMPANY LANDSCAPE
19.1 COMPANY SHARE ANALYSIS: EUROPE
20 SWOT ANALYSIS
21 COMPANY PROFILES
21.1 GSK PLC.
21.1.1 COMPANY SNAPSHOT
21.1.2 REVENUE ANALYSIS
21.1.3 PRODUCT PORTFOLIO
21.1.4 RECENT DEVELOPMENT
21.2 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
21.2.1 COMPANY SNAPSHOT
21.2.2 REVENUE ANALYSIS
21.2.3 PRODUCT PORTFOLIO
21.2.4 RECENT DEVELOPMENT
21.3 PFIZER INC.
21.3.1 COMPANY SNAPSHOT
21.3.2 REVENUE ANALYSIS
21.3.3 PRODUCT PORTFOLIO
21.3.4 RECENT DEVELOPMENT
21.4 TEVA PHARMACEUTICALS USA, INC.
21.4.1 COMPANY SNAPSHOT
21.4.2 REVENUE ANALYSIS
21.4.3 PRODUCT PORTFOLIO
21.4.4 RECENT DEVELOPMENT
21.5 NOVARTIS AG
21.5.1 COMPANY SNAPSHOT
21.5.2 REVENUE ANALYSIS
21.5.3 PRODUCT PORTFOLIO
21.5.4 RECENT DEVELOPMENT
21.6 ADVACARE PHARMA
21.6.1 COMPANY SNAPSHOT
21.6.2 PRODUCT PORTFOLIO
21.6.3 RECENT DEVELOPMENT
21.7 AMGEN INC.
21.7.1 COMPANY SNAPSHOT
21.7.2 REVENUE ANALYSIS
21.7.3 PRODUCT PORTFOLIO
21.7.4 RECENT DEVELOPMENT
21.8 ANOKION
21.8.1 COMPANY SNAPSHOT
21.8.2 PRODUCT PORTFOLIO
21.8.3 RECENT DEVELOPMENT
21.9 EQUILLIUM BIO.
21.9.1 COMPANY SNAPSHOT
21.9.2 PRODUCT PORTFOLIO
21.9.3 RECENT DEVELOPMENT
21.1 IMMUNIC THERAPEUTICS
21.10.1 COMPANY SNAPSHOT
21.10.2 PRODUCT PORTFOLIO
21.10.3 RECENT DEVELOPMENT
21.11 IMMUNOGENX, INC.
21.11.1 COMPANY SNAPSHOT
21.11.2 PRODUCT PORTFOLIO
21.11.3 RECENT DEVELOPMENT
21.12 SALIX PHARMACEUTICALS (SUBSIDIARY OF BAUSCH HEALTH COMPANIES INC.)
21.12.1 COMPANY SNAPSHOT
21.12.2 REVENUE ANALYSIS OF PARENT COMPANY
21.12.3 PRODUCT PORTFOLIO
21.12.4 RECENT DEVELOPMENT
21.13 TAKEDA PHARMACEUTICAL COMPANY LIMITED
21.13.1 COMPANY SNAPSHOT
21.13.2 REVENUE ANALYSIS
21.13.3 PRODUCT PORTFOLIO
21.13.4 RECENT DEVELOPMENT
21.14 TILLOTTS PHARMA AG
21.14.1 COMPANY SNAPSHOT
21.14.2 PRODUCT PORTFOLIO
21.14.3 RECENT DEVELOPMENT
21.15 TOPAS THERAPEUTICS
21.15.1 COMPANY SNAPSHOT
21.15.2 PRODUCT PORTFOLIO
21.15.3 RECENT DEVELOPMENT
22 QUESTIONNAIRE
23 RELATED REPORTS
Lista de Tablas
TABLE 1 PIPELINE ANALYSIS FOR NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET
TABLE 2 NORTH AMERICA CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 3 EUROPE CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 4 NORTH AMERICA CORTICOSTERIODS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 5 NORTH AMERICA CORTICOSTERIODS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 6 EUROPE CORTICOSTERIODS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 7 EUROPE CORTICOSTERIODS IN CELIAC DISEASE MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 8 NORTH AMERICA IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 9 NORTH AMERICA IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 10 EUROPE IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 11 EUROPE IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 12 NORTH AMERICA CELIAC DISEASE MARKET, BY DISEASE TYPE, 2022-2031 (USD THOUSAND)
TABLE 13 EUROPE CELIAC DISEASE MARKET, BY DISEASE TYPE, 2022-2031 (USD THOUSAND)
TABLE 14 NORTH AMERICA REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 15 EUROPE REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 16 NORTH AMERICA CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 17 EUROPE CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 18 NORTH AMERICA CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)
TABLE 19 EUROPE CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)
TABLE 20 NORTH AMERICA CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 21 EUROPE CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 22 NORTH AMERICA CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 23 EUROPE CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 24 NORTH AMERICA CORTICOSTERIODS IN CELIAC DISEASE MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 25 EUROPE CORTICOSTERIODS IN CELIAC DISEASE MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 26 NORTH AMERICA CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 27 EUROPE CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 28 NORTH AMERICA ADULTS IN CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 29 EUROPE ADULTS IN CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 30 NORTH AMERICA GERIATRIC IN CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 31 EUROPE GERAITRIC IN CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 32 NORTH AMERICA CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 33 EUROPE CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 34 NORTH AMERICA CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 35 EUROPE CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 36 NORTH AMERICA CELIAC DISEASE MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 37 U.S. CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 38 U.S. CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 39 U.S. CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 40 U.S. CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 41 U.S. IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 42 U.S. IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)
TABLE 43 U.S. IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 44 U.S. CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)
TABLE 45 U.S. REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 46 U.S. CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 47 U.S. CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)
TABLE 48 U.S. CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 49 U.S. CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 50 U.S. ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 51 U.S. CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 52 U.S. ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 53 U.S. GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 54 U.S. CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 55 U.S. CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 56 CANADA CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 57 CANADA CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 58 CANADA CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 59 CANADA CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 60 CANADA IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 61 CANADA IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)
TABLE 62 CANADA IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 63 CANADA CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)
TABLE 64 CANADA REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 65 CANADA CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 66 CANADA CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)
TABLE 67 CANADA CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 68 CANADA CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 69 CANADA ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 70 CANADA CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 71 CANADA ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 72 CANADA GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 73 CANADA CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 74 CANADA CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 75 MEXICO CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 76 MEXICO CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 77 MEXICO CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 78 MEXICO CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 79 MEXICO IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 80 MEXICO IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)
TABLE 81 MEXICO IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 82 MEXICO CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)
TABLE 83 MEXICO REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 84 MEXICO CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 85 MEXICO CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)
TABLE 86 MEXICO CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 87 MEXICO CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 88 MEXICO ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 89 MEXICO CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 90 MEXICO ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 91 MEXICO GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 92 MEXICO CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 93 MEXICO CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 94 EUROPE CELIAC DISEASE MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 95 GERMANY CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 96 GERMANY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 97 GERMANY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 98 GERMANY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 99 GERMANY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 100 GERMANY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)
TABLE 101 GERMANY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 102 GERMANY CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)
TABLE 103 GERMANY REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 104 GERMANY CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 105 GERMANY CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)
TABLE 106 GERMANY CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 107 GERMANY CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 108 GERMANY ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 109 GERMANY CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 110 GERMANY ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 111 GERMANY GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 112 GERMANY CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 113 GERMANY CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 114 FRANCE CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 115 FRANCE CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 116 FRANCE CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 117 FRANCE CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 118 FRANCE IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 119 FRANCE IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)
TABLE 120 FRANCE IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 121 FRANCE CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)
TABLE 122 FRANCE REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 123 FRANCE CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 124 FRANCE CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)
TABLE 125 FRANCE CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 126 FRANCE CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 127 FRANCE ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 128 FRANCE CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 129 FRANCE ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 130 FRANCE GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 131 FRANCE CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 132 FRANCE CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 133 ITALY CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 134 ITALY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 135 ITALY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 136 ITALY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 137 ITALY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 138 ITALY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)
TABLE 139 ITALY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 140 ITALY CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)
TABLE 141 ITALY REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 142 ITALY CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 143 ITALY CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)
TABLE 144 ITALY CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 145 ITALY CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 146 ITALY ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 147 ITALY CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 148 ITALY ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 149 ITALY GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 150 ITALY CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 151 ITALY CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 152 SPAIN CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 153 SPAIN CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 154 SPAIN CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 155 SPAIN CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 156 SPAIN IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 157 SPAIN IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)
TABLE 158 SPAIN IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 159 SPAIN CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)
TABLE 160 SPAIN REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 161 SPAIN CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 162 SPAIN CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)
TABLE 163 SPAIN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 164 SPAIN CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 165 SPAIN ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 166 SPAIN CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 167 SPAIN ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 168 SPAIN GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 169 SPAIN CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 170 SPAIN CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 171 U.K. CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 172 U.K. CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 173 U.K. CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 174 U.K. CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 175 U.K. IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 176 U.K. IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)
TABLE 177 U.K. IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 178 U.K. CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)
TABLE 179 U.K. REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 180 U.K. CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 181 U.K. CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)
TABLE 182 U.K. CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 183 U.K. CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 184 U.K. ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 185 U.K. CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 186 U.K. ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 187 U.K. GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 188 U.K. CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 189 U.K. CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 190 SWITZERLAND CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 191 SWITZERLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 192 SWITZERLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 193 SWITZERLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 194 SWITZERLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 195 SWITZERLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)
TABLE 196 SWITZERLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 197 SWITZERLAND CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)
TABLE 198 SWITZERLAND REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 199 SWITZERLAND CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 200 SWITZERLAND CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)
TABLE 201 SWITZERLAND CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 202 SWITZERLAND CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 203 SWITZERLAND ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 204 SWITZERLAND CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 205 SWITZERLAND ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 206 SWITZERLAND GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 207 SWITZERLAND CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 208 SWITZERLAND CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 209 NETHERLANDS CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 210 NETHERLANDS CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 211 NETHERLANDS CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 212 NETHERLANDS CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 213 NETHERLANDS IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 214 NETHERLANDS IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)
TABLE 215 NETHERLANDS IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 216 NETHERLANDS CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)
TABLE 217 NETHERLANDS REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 218 NETHERLANDS CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 219 NETHERLANDS CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)
TABLE 220 NETHERLANDS CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 221 NETHERLANDS CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 222 NETHERLANDS ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 223 NETHERLANDS CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 224 NETHERLANDS ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 225 NETHERLANDS GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 226 NETHERLANDS CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 227 NETHERLANDS CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 228 RUSSIA CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 229 RUSSIA CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 230 RUSSIA CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 231 RUSSIA CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 232 RUSSIA IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 233 RUSSIA IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)
TABLE 234 RUSSIA IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 235 RUSSIA CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)
TABLE 236 RUSSIA REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 237 RUSSIA CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 238 RUSSIA CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)
TABLE 239 RUSSIA CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 240 RUSSIA CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 241 RUSSIA ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 242 RUSSIA CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 243 RUSSIA ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 244 RUSSIA GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 245 RUSSIA CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 246 RUSSIA CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 247 TURKEY CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 248 TURKEY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 249 TURKEY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 250 TURKEY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 251 TURKEY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 252 TURKEY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)
TABLE 253 TURKEY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 254 TURKEY CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)
TABLE 255 TURKEY REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 256 TURKEY CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 257 TURKEY CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)
TABLE 258 TURKEY CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 259 TURKEY CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 260 TURKEY ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 261 TURKEY CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 262 TURKEY ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 263 TURKEY GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 264 TURKEY CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 265 TURKEY CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 266 POLAND CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 267 POLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 268 POLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 269 POLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 270 POLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 271 POLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)
TABLE 272 POLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 273 POLAND CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)
TABLE 274 POLAND REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 275 POLAND CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 276 POLAND CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)
TABLE 277 POLAND CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 278 POLAND CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 279 POLAND ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 280 POLAND CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 281 POLAND ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 282 POLAND GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 283 POLAND CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 284 POLAND CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 285 SWEDEN CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 286 SWEDEN CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 287 SWEDEN CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 288 SWEDEN CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 289 SWEDEN IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 290 SWEDEN IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)
TABLE 291 SWEDEN IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 292 SWEDEN CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)
TABLE 293 SWEDEN REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 294 SWEDEN CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 295 SWEDEN CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)
TABLE 296 SWEDEN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 297 SWEDEN CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 298 SWEDEN ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 299 SWEDEN CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 300 SWEDEN ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 301 SWEDEN GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 302 SWEDEN CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 303 SWEDEN CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 304 BELGIUM CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 305 BELGIUM CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 306 BELGIUM CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 307 BELGIUM CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 308 BELGIUM IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 309 BELGIUM IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)
TABLE 310 BELGIUM IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 311 BELGIUM CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)
TABLE 312 BELGIUM REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 313 BELGIUM CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 314 BELGIUM CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)
TABLE 315 BELGIUM CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 316 BELGIUM CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 317 BELGIUM ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 318 BELGIUM CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 319 BELGIUM ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 320 BELGIUM GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 321 BELGIUM CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 322 BELGIUM CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 323 DENMARK CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 324 DENMARK CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 325 DENMARK CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 326 DENMARK CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 327 DENMARK IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 328 DENMARK IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)
TABLE 329 DENMARK IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 330 DENMARK CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)
TABLE 331 DENMARK REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 332 DENMARK CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 333 DENMARK CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)
TABLE 334 DENMARK CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 335 DENMARK CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 336 DENMARK ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 337 DENMARK CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 338 DENMARK ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 339 DENMARK GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 340 DENMARK CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 341 DENMARK CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 342 FINLAND CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 343 FINLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 344 FINLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 345 FINLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 346 FINLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 347 FINLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)
TABLE 348 FINLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 349 FINLAND CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)
TABLE 350 FINLAND REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 351 FINLAND CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 352 FINLAND CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)
TABLE 353 FINLAND CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 354 FINLAND CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 355 FINLAND ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 356 FINLAND CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 357 FINLAND ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 358 FINLAND GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 359 FINLAND CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 360 FINLAND CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 361 NORWAY CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 362 NORWAY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 363 NORWAY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 364 NORWAY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 365 NORWAY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 366 NORWAY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)
TABLE 367 NORWAY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 368 NORWAY CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)
TABLE 369 NORWAY REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 370 NORWAY CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 371 NORWAY CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)
TABLE 372 NORWAY CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 373 NORWAY CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 374 NORWAY ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 375 NORWAY CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 376 NORWAY ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 377 NORWAY GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 378 NORWAY CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 379 NORWAY CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 380 REST OF EUROPE CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
Lista de figuras
FIGURE 1 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA CELIAC DISEASE MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 EUROPE CELIAC DISEASE MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 6 NORTH AMERICA CELIAC DISEASE MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 7 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 NORTH AMERICA CELIAC DISEASE MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE CELIAC DISEASE MARKET: DBMR MARKET POSITION GRID
FIGURE 10 NORTH AMERICA CELIAC DISEASE MARKET: MARKET END USER COVERAGE GRID
FIGURE 11 EUROPE CELIAC DISEASE MARKET: MARKET END USER COVERAGE GRID
FIGURE 12 NORTH AMERICA CELIAC DISEASE MARKET: VENDOR SHARE ANALYSIS
FIGURE 13 EUROPE CELIAC DISEASE MARKET: VENDOR SHARE ANALYSIS
FIGURE 14 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET: SEGMENTATION
FIGURE 15 THE INCREASING PREVALENCE OF CELIAC DISEASE IS DRIVING THE GROWTH OF THE NORTH AMERICA CELIAC DISEASE MARKET IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 16 RISING CONSUMPTION OF GLUTEN-CONTAINING PRODUCTS IS DRIVING THE GROWTH OF THE EUROPE CELIAC DISEASE MARKET IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 17 CORTICOSTEROIDS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA CELIAC DISEASE MARKET IN THE FORECAST PERIOD OF 2024 AND 2031
FIGURE 18 CARTICOSTEROIDS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE CELIAC DISEASE MARKET IN THE FORECAST PERIOD OF 2024 AND 2031
FIGURE 19 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET
FIGURE 20 NORTH AMERICA CELIAC DISEASE MARKET: BY TREATMENT TYPE, 2023
FIGURE 21 NORTH AMERICA CELIAC DISEASE MARKET: BY TREATMENT TYPE, 2024-2031 (USD THOUSAND)
FIGURE 22 NORTH AMERICA CELIAC DISEASE MARKET: BY TREATMENT TYPE, CAGR (2024-2031)
FIGURE 23 NORTH AMERICA CELIAC DISEASE MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 24 EUROPE CELIAC DISEASE MARKET: BY TREATMENT TYPE, 2023
FIGURE 25 EUROPE CELIAC DISEASE MARKET: BY TREATMENT TYPE, 2024-2031 (USD THOUSAND)
FIGURE 26 EUROPE CELIAC DISEASE MARKET: BY TREATMENT TYPE, CAGR (2024-2031)
FIGURE 27 EUROPE CELIAC DISEASE MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 28 NORTH AMERICA CELIAC DISEASE MARKET: BY DISEASE TYPE, 2023
FIGURE 29 NORTH AMERICA CELIAC DISEASE MARKET: BY DISEASE TYPE, 2024-2031 (USD THOUSAND)
FIGURE 30 NORTH AMERICA CELIAC DISEASE MARKET: BY DISEASE TYPE, CAGR (2024-2031)
FIGURE 31 NORTH AMERICA CELIAC DISEASE MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 32 EUROPE CELIAC DISEASE MARKET: BY DISEASE TYPE, 2023
FIGURE 33 EUROPE CELIAC DISEASE MARKET: BY DISEASE TYPE, 2024-2031 (USD THOUSAND)
FIGURE 34 EUROPE CELIAC DISEASE MARKET: BY DISEASE TYPE, CAGR (2024-2031)
FIGURE 35 EUROPE CELIAC DISEASE MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 36 NORTH AMERICA CELIAC DISEASE MARKET: BY DRUG TYPE, 2023
FIGURE 37 NORTH AMERICA CELIAC DISEASE MARKET: BY DRUG TYPE, 2024-2031 (USD THOUSAND)
FIGURE 38 NORTH AMERICA CELIAC DISEASE MARKET: BY DRUG TYPE, CAGR (2024-2031)
FIGURE 39 NORTH AMERICA CELIAC DISEASE MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 40 EUROPE CELIAC DISEASE MARKET: BY DRUG TYPE, 2023
FIGURE 41 EUROPE CELIAC DISEASE MARKET: BY DRUG TYPE, 2024-2031 (USD THOUSAND)
FIGURE 42 EUROPE CELIAC DISEASE MARKET: BY DRUG TYPE, CAGR (2024-2031)
FIGURE 43 EUROPE CELIAC DISEASE MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 44 NORTH AMERICA CELIAC DISEASE MARKET: BY PRESCRIPTION TYPE, 2023
FIGURE 45 NORTH AMERICA CELIAC DISEASE MARKET: BY PRESCRIPTION TYPE, 2024-2031 (USD THOUSAND)
FIGURE 46 NORTH AMERICA CELIAC DISEASE MARKET: BY PRESCRIPTION TYPE, CAGR (2024-2031)
FIGURE 47 NORTH AMERICA CELIAC DISEASE MARKET: BY PRESCRIPTION TYPE, LIFELINE CURVE
FIGURE 48 EUROPE CELIAC DISEASE MARKET: BY PRESCRIPTION TYPE, 2023
FIGURE 49 EUROPE CELIAC DISEASE MARKET: BY PRESCRIPTION TYPE, 2024-2031 (USD THOUSAND)
FIGURE 50 EUROPE CELIAC DISEASE MARKET: BY PRESCRIPTION TYPE, CAGR (2024-2031)
FIGURE 51 EUROPE CELIAC DISEASE MARKET: BY PRESCRIPTION TYPE, LIFELINE CURVE
FIGURE 52 NORTH AMERICA CELIAC DISEASE MARKET: BY DOSAGE FORM, 2023
FIGURE 53 NORTH AMERICA CELIAC DISEASE MARKET: BY DOSAGE FORM, 2024-2031 (USD THOUSAND)
FIGURE 54 NORTH AMERICA CELIAC DISEASE MARKET: BY DOSAGE FORM, CAGR (2024-2031)
FIGURE 55 NORTH AMERICA CELIAC DISEASE MARKET: BY DOSAGE FORM, LIFELINE CURVE
FIGURE 56 EUROPE CELIAC DISEASE MARKET: BY DOSAGE FORM, 2023
FIGURE 57 EUROPE CELIAC DISEASE MARKET: BY DOSAGE FORM, 2024-2031 (USD THOUSAND)
FIGURE 58 EUROPE CELIAC DISEASE MARKET: BY DOSAGE FORM, CAGR (2024-2031)
FIGURE 59 EUROPE CELIAC DISEASE MARKET: BY DOSAGE FORM, LIFELINE CURVE
FIGURE 60 NORTH AMERICA CELIAC DISEASE MARKET: BY ROUTE OF ADMINISTRATION, 2023
FIGURE 61 NORTH AMERICA CELIAC DISEASE MARKET: BY ROUTE OF ADMINISTRATION, 2024-2031 (USD THOUSAND)
FIGURE 62 NORTH AMERICA CELIAC DISEASE MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)
FIGURE 63 NORTH AMERICA CELIAC DISEASE MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 64 EUROPE CELIAC DISEASE MARKET: BY ROUTE OF ADMINISTRATION, 2023
FIGURE 65 EUROPE CELIAC DISEASE MARKET: BY ROUTE OF ADMINISTRATION, 2024-2031 (USD THOUSAND)
FIGURE 66 EUROPE CELIAC DISEASE MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)
FIGURE 67 EUROPE CELIAC DISEASE MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 68 NORTH AMERICA CELIAC DISEASE MARKET: BY POPULATION TYPE, 2023
FIGURE 69 NORTH AMERICA CELIAC DISEASE MARKET: BY POPULATION TYPE, 2024-2031 (USD THOUSAND)
FIGURE 70 NORTH AMERICA CELIAC DISEASE MARKET: BY POPULATION TYPE, CAGR (2024-2031)
FIGURE 71 NORTH AMERICA CELIAC DISEASE MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 72 EUROPE CELIAC DISEASE MARKET: BY POPULATION TYPE, 2023
FIGURE 73 EUROPE CELIAC DISEASE MARKET: BY POPULATION TYPE, 2024-2031 (USD THOUSAND)
FIGURE 74 EUROPE CELIAC DISEASE MARKET: BY POPULATION TYPE, CAGR (2024-2031)
FIGURE 75 EUROPE CELIAC DISEASE MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 76 NORTH AMERICA CELIAC DISEASE MARKET: BY END USER, 2023
FIGURE 77 NORTH AMERICA CELIAC DISEASE MARKET: BY END USER, 2024-2031 (USD THOUSAND)
FIGURE 78 NORTH AMERICA CELIAC DISEASE MARKET: BY END USER, CAGR (2024-2031)
FIGURE 79 NORTH AMERICA CELIAC DISEASE MARKET: BY END USER, LIFELINE CURVE
FIGURE 80 EUROPE CELIAC DISEASE MARKET: BY END USER, 2023
FIGURE 81 EUROPE CELIAC DISEASE MARKET: BY END USER, 2024-2031 (USD THOUSAND)
FIGURE 82 EUROPE CELIAC DISEASE MARKET: BY END USER, CAGR (2024-2031)
FIGURE 83 EUROPE CELIAC DISEASE MARKET: BY END USER, LIFELINE CURVE
FIGURE 84 NORTH AMERICA CELIAC DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 85 NORTH AMERICA CELIAC DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD THOUSAND)
FIGURE 86 NORTH AMERICA CELIAC DISEASE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 87 NORTH AMERICA CELIAC DISEASE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 88 EUROPE CELIAC DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 89 EUROPE CELIAC DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD THOUSAND)
FIGURE 90 EUROPE CELIAC DISEASE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 91 EUROPE CELIAC DISEASE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 92 NORTH AMERICA CELIAC DISEASE MARKET: SNAPSHOT (2023)
FIGURE 93 EUROPE CELIAC DISEASE MARKET: SNAPSHOT (2023)
FIGURE 94 NORTH AMERICA CELIAC DISEASE MARKET: COMPANY SHARE 2023 (%)
FIGURE 95 EUROPE CELIAC DISEASE MARKET: COMPANY SHARE 2023 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
